Latest total revenue for ATTBF: $360K, below the Healthcare sector average of $110B.
Get informed when a big investor buys or sells
+ FollowAs of Sep 2019
Trailing 12 months ending Sep 2019
Abattis Bioceuticals (ATTBF) currently reports a total revenue of $360K as of September 2019. That compares with $8.4K in the prior-year period — up 4163.2% year over year. That is below the Healthcare sector average of $110B. Use the charts on this page to explore Abattis Bioceuticals's total revenue history and peer comparisons.
Abattis Bioceuticals's total revenue increased from $8.4K to $360K — a 4163.2% year-over-year increase (period ending September 2019). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
Abattis Bioceuticals's total revenue of $360K is lower than the Healthcare sector average of $110B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
Abattis Bioceuticals reported $360K in total revenue as of September 2019. That compares with $8.4K in the prior-year period — up 4163.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current total revenue of $360K, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $110B. From there, open related valuation or income-statement pages for Abattis Bioceuticals, and consider following ATTBF for alerts when major investors trade the stock.